 Xeris Pharmaceuticals acquired Strongbridge Biopharma in a stock swap and contingent value rights transaction. The combined company is now called Xeris Biopharma Holdings. Recorlev is ready for approval in Endogenous Cushings Syndrome. The FDA set the PDUFA date for January 1st of 2021. If Recorlev is approved, Xeris could have three products. 